MX2014003194A - 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina. - Google Patents

3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.

Info

Publication number
MX2014003194A
MX2014003194A MX2014003194A MX2014003194A MX2014003194A MX 2014003194 A MX2014003194 A MX 2014003194A MX 2014003194 A MX2014003194 A MX 2014003194A MX 2014003194 A MX2014003194 A MX 2014003194A MX 2014003194 A MX2014003194 A MX 2014003194A
Authority
MX
Mexico
Prior art keywords
formula
tyrosine kinase
compound
pyradines
ylthio
Prior art date
Application number
MX2014003194A
Other languages
English (en)
Other versions
MX339302B (es
Inventor
Fang Liang
Chao Chen
Haibing Deng
Haibing Guo
Feng He
Lei Jiang
Yaun Mi
Huixin Wan
Yao-Chang Xu
Hongping Yu
Ji Yue Jeff Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2014003194A publication Critical patent/MX2014003194A/es
Publication of MX339302B publication Critical patent/MX339302B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La invención se refiere a los compuestos de la fórmula (I) y a las sales de los mismos; ver fórmula (I), en donde los sustituyentes son como se definen en la memoria descriptiva; a un compuesto de la fórmula (I) para usarse en el tratamiento del cuerpo humano o animal, en particular con respecto a las enfermedades o condiciones mediadas por la cinasa de tirosina c-Met; el uso de un compuesto de la fórmula (I) para la elaboración de un medicamento para el tratamiento de estas enfermedades; a las composiciones farmacéuticas que comprenden un compuesto de la fórmula (I), opcionalmente en la presencia de un componente de combinación, y a los procesos para la preparación de un compuesto de la fórmula (I).
MX2014003194A 2011-09-15 2012-09-13 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina. MX339302B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2011079695 2011-09-15
CN2012079055 2012-07-23
PCT/IB2012/054775 WO2013038362A1 (en) 2011-09-15 2012-09-13 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase

Publications (2)

Publication Number Publication Date
MX2014003194A true MX2014003194A (es) 2015-03-19
MX339302B MX339302B (es) 2016-05-19

Family

ID=46981017

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003194A MX339302B (es) 2011-09-15 2012-09-13 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.

Country Status (14)

Country Link
US (2) US9062045B2 (es)
EP (1) EP2755976B1 (es)
JP (1) JP5957526B2 (es)
KR (1) KR20140077916A (es)
AR (1) AR087868A1 (es)
AU (1) AU2012310168B2 (es)
BR (1) BR112014006223A8 (es)
CA (1) CA2848809A1 (es)
EA (1) EA026655B1 (es)
ES (1) ES2691650T3 (es)
MX (1) MX339302B (es)
TW (1) TW201319067A (es)
UY (1) UY34329A (es)
WO (1) WO2013038362A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015027440B1 (pt) * 2013-05-10 2023-04-11 Jiangsu Hansoh Pharmaceutical Co., Ltd Derivado de [1,2,4]triazol[4,3-a]piridina, seus usos e seu processo de preparação, e composição farmacêutica
JP6585589B2 (ja) 2013-06-24 2019-10-02 アムジエン・インコーポレーテツド ［１，２，４］−トリアゾロ［４，３−ａ］ピリジンの調製のための方法
GB201321742D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
JP6537591B2 (ja) * 2014-08-01 2019-07-03 ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド ｃ−Ｍｅｔ阻害剤の結晶性フリー塩基またはそれらの結晶性酸性塩、およびそれらの製造方法および用途
US10301325B2 (en) 2015-09-24 2019-05-28 Shanghai Haiju Biological Technology Co., Ltd. Quinoline derivative, and pharmaceutical composition, preparation method and use thereof
CN106883250B (zh) * 2015-12-15 2021-05-18 江苏豪森药业集团有限公司 C-Met酪氨酸激酶抑制剂的制备方法
US11528907B2 (en) 2018-04-25 2022-12-20 Bayer Aktiengesellschaft Heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides
BR112022000942A2 (pt) 2019-07-23 2022-05-17 Bayer Ag Compostos de heteroaril-triazol como pesticidas
AU2020317609A1 (en) 2019-07-23 2022-02-24 Bayer Aktiengesellschaft Novel heteroaryl-triazole compounds as pesticides
CN111440174B (zh) * 2020-04-02 2021-07-09 广州医科大学 一种吡啶酰胺类化合物及其制备方法与应用

Family Cites Families (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4358453A (en) 1982-01-08 1982-11-09 Schering Corporation 1,2,4-Triazolo[4,3-a]pyridines
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
FR2601952B1 (fr) 1986-07-23 1988-11-25 Carpibem Nouveaux derives amino alkyl thio de triazolopyridine ou triazoloquinoline, leurs procedes de preparation, medicaments les contenant, utiles notamment comme antalgiques
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
GB8916480D0 (en) 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
US5451700A (en) 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
WO1993019751A1 (en) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
CZ283425B6 (cs) 1992-04-02 1998-04-15 Smithkline Beecham Corporation Fenylové deriváty a farmaceutické prostředky s jejich obsahem
WO1993019750A1 (en) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating allergic or inflammatory diseases
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
BR9207175A (pt) 1992-10-28 1995-12-12 Genentech Inc Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE4326758A1 (de) 1993-08-10 1995-02-16 Basf Ag [1,3,4]Triazolo[1,5-a]pyridine
DE4329296A1 (de) 1993-08-31 1995-03-02 Basf Ag Azofarbstoffe mit einer Diazokomponente aus der Anilinreihe und Kupplungskomponente aus der Triazolopyridinreihe
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9414208D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
WO1996030347A1 (en) 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
CZ1598A3 (cs) 1995-07-06 1998-04-15 Novartis Ag Pyrrolopyrimidiny a způsoby jejich přípravy
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
BR9709959A (pt) 1996-06-24 2000-05-09 Pfizer Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
DE69724269T2 (de) 1996-09-06 2004-06-09 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
ATE408612T1 (de) 1996-11-18 2008-10-15 Biotechnolog Forschung Gmbh Epothilone e und f
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
GB9723566D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723589D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
CO4990969A1 (es) 1998-02-14 2000-12-26 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
AU758526B2 (en) 1998-02-25 2003-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
EA200001224A1 (ru) 1998-06-23 2001-08-27 Глаксо Груп Лимитед Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
GB9813540D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813565D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
CA2335094C (en) 1998-06-30 2008-12-23 The Dow Chemical Company Polymer polyols and a process for the production thereof
US6303625B1 (en) 1998-07-27 2001-10-16 Ortho-Mcneil Pharmaceutical, Inc. Triazolopyridines for the treatment of thrombosis disorders
CN1152031C (zh) 1998-08-11 2004-06-02 诺瓦提斯公司 具有血管生成抑制活性的异喹啉衍生物
BR9914526A (pt) 1998-10-16 2001-07-03 Pfizer Derivados de adenina
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
KR20070087132A (ko) 1998-11-20 2007-08-27 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법및 물질
IL143596A0 (en) 1998-12-22 2002-04-21 Genentech Inc Vascular endothelial cell growth factor antagonists and uses thereof
CA2366857C (en) 1999-03-30 2010-12-14 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
ES2246233T3 (es) 1999-05-04 2006-02-16 Schering Corporation Derivados de piperidina utiles como antagonistas de ccr5.
ES2244437T3 (es) 1999-05-04 2005-12-16 Schering Corporation Derivados de piperazina utiles como antagonistas de ccr5.
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6333335B1 (en) 1999-07-23 2001-12-25 Merck & Co., Inc. Phenyl-protein transferase inhibitors
PL200923B1 (pl) 1999-08-21 2009-02-27 Nycomed Gmbh Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
CO5180581A1 (es) 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
GB9924363D0 (en) 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
TWI227240B (en) 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
GB0015727D0 (en) 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
US6916828B2 (en) 2000-06-27 2005-07-12 Laboratorios S.A.L.V.A.T., S.A. Carbamates derivatived from arylakylamines
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
DE10038019A1 (de) 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
AU2001275760B2 (en) 2000-08-05 2005-03-17 Glaxo Group Limited 6.alpha., 9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid S-fluoromethyl ester as an anti-inflammatory agent
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
PL362989A1 (en) 2000-12-22 2004-11-15 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists
SK287414B6 (sk) 2000-12-28 2010-09-07 Laboratorios Almirall, S.A. Chinuklidínové deriváty a kompozície s ich obsahom
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
HUP0400070A2 (hu) 2001-04-30 2004-04-28 Glaxo Group Limited 17alfa-helyzetben ciklusos észtercsoportot tartalmazó androsztán-17béta-karbotiosav-észter-származékok mint gyulladásgátló szerek, eljárás a vegyületek előállítására és ezeket tartalmazó gyógyszerkészítmények
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
PA8546101A1 (es) 2001-05-25 2003-12-10 Pfizer Un antagonista de a2a en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas
JP2005500290A (ja) 2001-06-12 2005-01-06 グラクソ　グループ　リミテッド 抗炎症性の、１７β−カルボチオアートアンドロスタン誘導体である１７α複素環エステル
EP2327767B1 (en) 2001-06-21 2015-04-29 BASF Enzymes LLC Nitrilases
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
CZ2004501A3 (cs) 2001-10-17 2004-09-15 Ucb, S.A. Chinuklidinové deriváty, způsoby jejich přípravy a jejich použití jako M2 a/nebo M3 inhibitoru muskarinového receptoru
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
MY130622A (en) 2001-11-05 2007-07-31 Novartis Ag Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
WO2003048181A1 (en) 2001-12-01 2003-06-12 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
HUP0500107A3 (en) 2001-12-20 2011-05-30 Chiesi Farma Spa 1-alkyl-1-azoniabicyclo[2.2.2.]octane carbamate derivatives, pharmaceutical compositions comprising thereof and their use as muscarinic receptor antagonists
WO2003072592A1 (en) 2002-01-15 2003-09-04 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
AU2003201693A1 (en) 2002-01-21 2003-09-02 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
EP1490317A1 (en) 2002-03-26 2004-12-29 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EA008830B1 (ru) 2002-03-26 2007-08-31 Бёрингер Ингельхайм Фармасьютиклз, Инк. Миметики глюкокортикоидов, способы их получения, фармацевтические композиции и их применение
US20090170803A1 (en) 2002-04-10 2009-07-02 Linden Joel M Adjunctive treatment of biological diseases
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2201907B1 (es) 2002-05-29 2005-06-01 Almirall Prodesfarma, S.A. Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos.
DE10224888A1 (de) 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10225574A1 (de) 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
DE10227269A1 (de) 2002-06-19 2004-01-08 Merck Patent Gmbh Thiazolderivate
EP1517895B1 (en) 2002-06-25 2007-03-14 Merck Frosst Canada Ltd. 8-(biaryl) quinoline pde4 inhibitors
AU2003281219A1 (en) 2002-07-02 2004-01-23 Bernard Cote Di-aryl-substituted-ethane pyridone pde4 inhibitors
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
ES2518940T3 (es) 2002-07-08 2014-11-06 Pfizer Products Inc. Moduladores del receptor de glucocorticoides
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
PL373597A1 (en) 2002-08-10 2005-09-05 Altana Pharma Ag Piperidine-n-oxide-derivatives
WO2004018449A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
EP1556049A1 (en) 2002-08-10 2005-07-27 ALTANA Pharma AG Piperidine-pyridazones and phthalazones as pde4 inhibitors
PL373146A1 (en) 2002-08-10 2005-08-22 Altana Pharma Ag Pyridazinone-derivatives as pde4 inhibitors
RS20050116A (en) 2002-08-17 2007-11-15 Altana Pharma Ag., Novel phenanthridines
CA2495603A1 (en) 2002-08-17 2004-03-04 Altana Pharma Ag Benzonaphthyridines with pde 3/4 inhibiting activity
SE0202483D0 (sv) 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
DE60231341D1 (de) 2002-08-23 2009-04-09 Ranbaxy Lab Ltd Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
CA2495827C (en) 2002-08-29 2012-05-08 Altana Pharma Ag 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
JP4587295B2 (ja) 2002-08-29 2010-11-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビターとしての３−ヒドロキシ−６−フェニルフェナントリジン
JP2006508914A (ja) 2002-08-30 2006-03-16 ファイザー・プロダクツ・インク トリアゾロ−ピリジン製造のための新規な方法および中間体
JP2006096662A (ja) 2002-09-18 2006-04-13 Sumitomo Pharmaceut Co Ltd 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤
CA2497903A1 (en) 2002-09-18 2004-04-01 Ono Pharmaceutical Co., Ltd. Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
JP2004107299A (ja) 2002-09-20 2004-04-08 Japan Energy Corp 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤
DE10246374A1 (de) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
AP2021A (en) 2002-10-23 2009-08-03 Glenmark Pharmaceuticals Ltd Novel tricyclic compounds useful for the treatmentof inflammatory and allergic disorders: Process f or their preparation and pharmaceutical compositions containing them
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
DE10253220A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10253426B4 (de) 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2005007621A2 (en) 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US20050256309A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
US7205316B2 (en) 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
WO2006018727A2 (en) 2004-08-18 2006-02-23 Pharmacia & Upjohn Company Llc Triazolopyridine compounds useful for the treatment of inflammation
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
WO2006091897A2 (en) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
ME02736B (me) 2005-12-21 2017-10-20 Janssen Pharmaceutica Nv Triazolopiridazini kao modulatori tirozin kinaze
CN101415730B (zh) 2006-03-30 2013-04-10 诺瓦提斯公司 c-Met抗体的组合物和使用方法
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
EP2032578A2 (en) 2006-05-30 2009-03-11 Pfizer Products Incorporated Triazolopyridazine derivatives
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
AU2007309237B2 (en) 2006-10-23 2012-03-22 Sgx Pharmaceuticals, Inc. Triazolo-pyridazine protein kinase modulators
KR20090071612A (ko) * 2006-10-23 2009-07-01 에스지엑스 파마슈티컬스, 인코포레이티드 단백질 키나제 조정제로서의 바이시클릭 트리아졸
SI3034075T1 (sl) 2006-11-22 2018-12-31 Incyte Holdings Corporation Imidazotriazini in imidazopirimidini kot inhibitorji kinaze
EP2170894A1 (en) 2007-06-21 2010-04-07 Janssen Pharmaceutica N.V. Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
WO2009026717A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US20110039856A1 (en) 2007-11-29 2011-02-17 Pfizer Inc. Polymorphs of a c-met/hgfr inhibitor
WO2009073777A1 (en) 2007-12-06 2009-06-11 Schering Corporation Gamma secretase modulators
AU2009218459A1 (en) 2008-02-28 2009-09-03 Novartis Ag Imidazo [1,2-B] pyridazine derivatives for the treatment of C-Met tyrosine kinase mediated disease
NZ589622A (en) 2008-05-21 2012-10-26 Incyte Corp Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
EP2310366A2 (fr) 2008-07-18 2011-04-20 Sanofi-Aventis NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
UY32049A (es) * 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
FR2941949B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8263776B2 (en) 2009-05-28 2012-09-11 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met protein kinase
SI2464645T1 (sl) 2009-07-27 2017-10-30 Gilead Sciences, Inc. Zlite heterociklične spojine kot ionsko kanalni modulatorji
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2464649A1 (en) 2009-08-12 2012-06-20 Novartis AG Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
IN2012DN01453A (es) 2009-08-20 2015-06-05 Novartis Ag
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
US9163015B2 (en) 2010-02-11 2015-10-20 Vanderbilt University Pyrazolopyridine, pyrarolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
EP2425830A1 (en) 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
WO2012044577A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
US20120100157A1 (en) 2010-10-11 2012-04-26 Van Andel Research Institute Biomarker and Method for Predicting Sensitivity to MET Inhibitors
WO2012107500A1 (en) * 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase

Also Published As

Publication number Publication date
UY34329A (es) 2013-04-30
WO2013038362A1 (en) 2013-03-21
EP2755976B1 (en) 2018-07-18
KR20140077916A (ko) 2014-06-24
AU2012310168B2 (en) 2015-07-16
US9062045B2 (en) 2015-06-23
CA2848809A1 (en) 2013-03-21
US20130245002A1 (en) 2013-09-19
MX339302B (es) 2016-05-19
BR112014006223A2 (pt) 2017-04-11
TW201319067A (zh) 2013-05-16
ES2691650T3 (es) 2018-11-28
EP2755976A1 (en) 2014-07-23
AR087868A1 (es) 2014-04-23
JP5957526B2 (ja) 2016-07-27
EA026655B1 (ru) 2017-05-31
US9474762B2 (en) 2016-10-25
US20150250799A1 (en) 2015-09-10
AU2012310168A1 (en) 2014-05-01
JP2014526499A (ja) 2014-10-06
BR112014006223A8 (pt) 2018-01-09
EA201490630A1 (ru) 2014-08-29

Similar Documents

Publication Publication Date Title
IN2012DN01453A (es)
MX339302B (es) 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
MX2010009414A (es) Derivados de imidazo-[1,2-b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met.
MX2012001838A (es) Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
TN2011000263A1 (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
CA2918938C (en) Substituted aminopyrimidine compounds and methods of use
TN2012000249A1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
EP2650293A8 (en) [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof
EA201291348A1 (ru) Активаторы растворимой гуанилатциклазы
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
WO2012034055A3 (en) Compounds as c-met kinase inhibitors
MX2009008953A (es) Compuestos como inhibidores de angiogenesis.
MX2009009843A (es) Compuestos espiro sustituidos como inhibidores de la angiogenesis.
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
MX2013004298A (es) Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa.
EA201390198A1 (ru) Гетероциклическое соединение
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
AU2009282962A8 (en) Compounds as kinase inhibitors
MX2012001529A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-piridazin-6-ilo como moduladores de cinasa de tirosina c-met.
WO2016010869A3 (en) FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
AU2010275640A8 (en) Benzoquinolizinium salt derivatives as anticancer agents
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MX2008013477A (es) Compuestos biciclicos de tetrahidropirrol.
TN2010000390A1 (en) Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease

Legal Events

Date Code Title Description
FG Grant or registration